News & Media

Explore what’s happening here

Sumitomo Pharma Oncology (SMP Oncology) is advancing innovative science and transforming new discoveries into meaningful therapeutic options for patients with cancer. To learn more about our most recent discoveries, commercial efforts, and cancer care projects, see our press releases and other news below.

To contact our media relations staff, click here.

As of April 1, 2022 Sumitomo Dainippon Pharma Oncology (SDP Oncology) will be known as Sumitomo Pharma Oncology (SMP Oncology). Moving forward, all new publications and press releases will reflect our updated company name.

Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
06/08/2022

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TP-3654, the company's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.

Read more

Sumitomo Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Annual Meeting 2022
04/08/2022

Sumitomo Pharma Oncology, Inc., (SMP Oncology) a clinical-stage company focused on research and development for novel cancer therapeutics, today announced it will present new clinical and preclinical data on a range of investigational agents from the company's pipeline at the American Association for Cancer Research (AACR) Annual Meeting, held April 8-13, 2022, in New Orleans, LA.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of DSP-5336 in Patients with Acute Leukemia with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation
03/29/2022

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of menin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).

Read more

Sumitomo Dainippon Pharma Oncology Appoints Jatin J. Shah, M.D. as Chief Medical Officer
02/22/2022

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today announced the appointment of Jatin J. Shah, M.D. as Executive Vice President, Chief Medical Officer and Global Head of Development. In this new position Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline.

Read more

Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
12/14/2021

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage biopharmaceutical company focused on research and development for novel cancer therapeutics, today announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.

Read more

BYU researchers discover, then find way to attack 'cancer driver' gene
11/09/2021

Ladd Egan / KSL-TV
SDP Oncology is involved in a preclinical research collaboration with Josh Andersen Ph.D. and his team of scientists at Brigham Young University (BYU). Through this relationship, Dr. Andersen, who is a consultant for SDP Oncology, and the team at BYU worked with SDP Oncology to understand the mechanisms by which TNK1 is regulated. SDP Oncology's discovery sciences team also developed TNK1 inhibitors, including TP-5801, the compound used by Dr. Andersen in his research. This work was recently published in Nature Communications and Steve Warner, Ph.D., Senior Vice President, Head of US Research at SDP Oncology, spoke to KSL about developing a compound to target TNK1.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma
11/03/2021

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
10/21/2021

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1 study evaluating its investigational agent DSP-0390, an emopamil-binding protein (EBP) inhibitor, for the treatment of patients with recurrent high-grade glioma.

Read more

Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
04/10/2021

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company's pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.

Read more

Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study of Napabucasin Fails to Reach Primary Endpoints in Patients with Previously Treated Metastatic Colorectal Cancer
02/09/2021

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS). Napabucasin in combination with FOLFIRI failed to show significant OS improvement in the general study population and in patients whose tumor was positive for the phosphorylated signal transducer and activator of transcription 3 (pSTAT3) biomarker.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
01/19/2021

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).

Read more

Novel Cancer Vaccine DSP-7888 Proceeds to Phase 2 in Ovarian Cancer, First Patient Dosed
12/02/2020

Jessica Hergert / OncLive

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 Dose-Expansion Portion of Study Evaluating Investigational WT1 Immunotherapeutic Cancer Vaccine DSP-7888 (ombipepimut-S*) in Patients with Ovarian Cancer
10/27/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in patients with platinum-resistant ovarian cancer (PROC).

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
10/23/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia (AML) who have TP53 mutations and/or complex karyotype. This study is a new arm included in The Leukemia & Lymphoma Society's (LLS) groundbreaking Beat AML Master Clinical Trial.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with TP-1454 in Patients with Advanced Solid Tumors
10/09/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.

Read more

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
09/18/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors. These results were presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020.

Read more

The Alliance and TrialJectory report on collaboration to improve access to advanced cancer treatment
09/14/2020

Colorectal Cancer Alliance

Read more

Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
09/11/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020. Data will be shared during the Developmental Therapeutics Mini-Oral Presentation and include findings from a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of dubermatinib in patients with advanced solid tumors.

Read more

Japan’s Sumitomo merges oncology arms Tolero Pharma, Boston Biomedical
07/03/2020

Leslie Shaffer / Deal Street Asia

Read more

An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on 'new biology'
07/01/2020

John Carroll / Endpoints News

Read more

Sumitomo merges U.S. biotechs to create oncology division
07/01/2020

Nick Paul Taylor / FierceBiotech

Read more

Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
07/01/2020

Sumitomo Dainippon Pharma Oncology Advances Meaningful Therapies for Cancer Patients through Innovative Drug Discovery, Research and Development.

Read more

Disclaimer

By clicking on a link on this page, you may exit the SMP Oncology website for a third party website. Links which take you out of the SMP Oncology website are not under the control of SMP Oncology, and SMP Oncology is not responsible for the contents of any such site or any further links from such site. SMP Oncology is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by SMP Oncology. The website that you have requested also may not be optimized for your screen size.